Volitinib dihydrochloride - AZD6094 dihydrochloride | HMPL-504 dihydrochloride | Savolitinib dihydrochloride

Based on 85 reference(s) in Google Scholar 8 10 85

Axon 3864

CAS [N.A.]

MF C17H15N9.2HCl
MW 418.28

  • Purity: 99%
  • Optical purity: 99%
  • Soluble in DMSO

Volitinib dihydrochloride


Volitinib is an orally bioavailable ATP-competitive small molecule c-Met kinase inhibitor, binding to the enzyme potently with IC50 of 4 nM, and highly selective (>650 fold selectivity) over a panel of 265 kinases. Demonstrated selectivity for MET-driven disease, with MET amplified cell lines being most sensitive (IC50s of 1nM), and Displayed pote+DJ2869nt anti-tumor activity in cMET-dysregulated GC patient-derived tumor xenograft (PDX) models.

KEYWORDS: Volitinib dihydrochloride | Supplier | c-Met kinase inhibitor | AZD6094 dihydrochloride | HMPL-504 dihydrochloride | Savolitinib dihydrochloride | AZD-6094 | AZD 6094 | HMPL504 | HMPL 504 | CT-A6094 | CAS [N.A.] | [1313725-88-0] | HGF | c-MET | Inhibitor | Receptors

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...